

Giorgia Marisi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9101850/publications.pdf>

Version: 2024-02-01

48
papers

1,405
citations

304701

22
h-index

345203

36
g-index

50
all docs

50
docs citations

50
times ranked

2701
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?. International Journal of Molecular Sciences, 2018, 19, 3733.	4.1	147
2	Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?. World Journal of Gastroenterology, 2018, 24, 4152-4163.	3.3	134
3	Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-13.	4.0	106
4	Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget, 2016, 7, 67142-67149.	1.8	91
5	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. European Journal of Cancer, 2017, 86, 106-114.	2.8	76
6	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opinion on Pharmacotherapy, 2015, 16, 2719-2725.	1.8	66
7	Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2018, 19, 307.	4.1	56
8	Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Digestive and Liver Disease, 2019, 51, 681-688.	0.9	49
9	Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2019, 8, 131.	2.4	42
10	¹ H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages. Cancers, 2020, 12, 241.	3.7	39
11	Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. International Journal of Molecular Sciences, 2017, 18, 1240.	4.1	38
12	Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget, 2016, 7, 46678-46691.	1.8	35
13	eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. Journal of Translational Medicine, 2015, 13, 258.	4.4	33
14	Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Scientific Reports, 2017, 7, 42499.	3.3	30
15	Radiofrequency Ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival. OncoTargets and Therapy, 2018, Volume 11, 6555-6567.	2.0	30
16	eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget, 2016, 7, 27988-27999.	1.8	30
17	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS ONE, 2020, 15, e0232449.	2.5	29
18	Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC Cancer, 2016, 16, 429.	2.6	28

#	ARTICLE	IF	CITATIONS
19	<p>Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2981-2988.	2.0	26
20	Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. <i>Oncotarget</i> , 2016, 7, 15243-15251.	1.8	26
21	Role of SIRT-3, p-mTOR and HIF-1 α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1503.	4.1	24
22	Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2017, 12, 795-803.	3.6	23
23	ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. <i>Cancers</i> , 2019, 11, 1023.	3.7	23
24	<p>Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response) Tj ETQq0 0 0 rgB/Overloza 10 Tf 50	1.5	21
25	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. <i>Gastrointestinal Tumors</i> , 2019, 6, 92-107.	0.7	22
26	Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. <i>Scientific Reports</i> , 2017, 7, 1293.	3.3	21
27	<p>Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CI: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study</p>. <i>Cancer Management and Research</i> . 2019, Volume 11, 4357-4369.	1.9	17
28	Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial. <i>Oncotarget</i> , 2016, 7, 10193-10202.	1.8	15
29	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018, 104, 476-479.	1.1	14
30	Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs. <i>Cancers</i> , 2020, 12, 1272.	3.7	14
31	Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , 2020, 26, 4485-4493.	7.0	13
32	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 773-785.	3.6	12
33	Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. <i>Oncotarget</i> , 2017, 8, 66699-66708.	1.8	11
34	Discrepancies between VEGF \sim 1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue. <i>International Journal of Molecular Sciences</i> , 2014, 15, 13333-13343.	4.1	10
35	Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report. <i>BMC Cancer</i> , 2016, 16, 118.	2.6	9
36	IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab. <i>Cancer Management and Research</i> , 2018, Volume 10, 5659-5666.	1.9	8

#	ARTICLE	IF	CITATIONS
37	Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, e76-e78.	1.5	7
38	Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis. <i>Cancers</i> , 2021, 13, 213.	3.7	6
39	Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3532.	4.1	5
40	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. <i>Gastrointestinal Tumors</i> , 2019, 6, 71-80.	0.7	4
41	Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. <i>Epigenomics</i> , 2022, 14, 507-517.	2.1	4
42	Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4305-4308.	2.0	1
43	Recent Research on Gastrointestinal Carcinoma. <i>Cancers</i> , 2021, 13, 333.	3.7	1
44	Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colon rectal cancer: Results from the ITACa trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 617-617.	1.6	1
45	Prognostic and predictive role of circulating eNOS and EPHB4 in metastatic colorectal cancer patients receiving bevacizumab.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23083-e23083.	1.6	1
46	Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences. <i>Frontiers in Pharmacology</i> , 2021, 12, 745701.	3.5	1
47	Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 6346.	3.7	1
48	Effect of metformin on clinical outcome in advanced HCC patients receiving sorafenib.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15156-e15156.	1.6	0